Loading cancer entity…
Loading cancer entity…
Clinical trials
3,221 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (571)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02941744 | A Clinical Trial: Adjuvant Low-dose Ipilimumab + Nivolumab After Resection of Melanoma Macrometastases(ipniv) | completed | Phase 1 / Phase 2 | 56 | Universitair Ziekenhuis BrusselOTHER | 1 | Jan 24, 2019 | clinicaltrials |
| NCT02296996 | Dabrafenib and Trametinib for BRAF-inhibitor Pretreated Patients | completed | Phase 2 | 25 | Universitair Ziekenhuis BrusselOTHER | 1 | Jan 23, 2019 |
| NCT01069627 | A Study of Avastin (Bevacizumab) in Combination With Fotemustine in Patients With Metastatic Melanoma | completed | Phase 2 | 20 | Hoffmann-La RocheINDUSTRY | 1 | Dec 6, 2018 | clinicaltrials |
| NCT00788775 | Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma | completed | Phase 2 | 20 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 15, 2018 | clinicaltrials |
| NCT00027586 | Imatinib Mesylate in Treating Patients With Metastatic Melanoma | completed | Phase 2 | 22 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 31, 2018 | clinicaltrials |
| NCT01200238 | STA-9090(Ganetespib) in Metastatic Ocular Melanoma | completed | Phase 2 | 17 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 18, 2018 | clinicaltrials |
| NCT00404235 | Carboplatin and ABI-007 in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery | completed | Phase 2 | 76 | Alliance for Clinical Trials in OncologyOTHER | 1 | Oct 16, 2018 | clinicaltrials |
| NCT00861913 | Pazopanib Hydrochloride in Treating Patients With Metastatic Melanoma That Cannot be Removed by Surgery | completed | Phase 2 | 13 | National Cancer Institute (NCI)NIH | 1 | Oct 16, 2018 | clinicaltrials |
| NCT01666418 | Pilot Study Investigating the Metabolic Activity and Transcriptional Profiling in Vivo in Tumor Biopsies in Melanoma Patients During Treatment With Pazopanib Alone and in Combination With Paclitaxel | completed | Phase 2 | 19 | University of ZurichOTHER | 1 | Oct 16, 2018 | clinicaltrials |
| NCT02272855 | A Study of Combination Treatment With HF10 and Ipilimumab in Patients With Unresectable or Metastatic Melanoma | completed | Phase 2 | 46 | Takara Bio Inc.INDUSTRY | 1 | Sep 26, 2018 | clinicaltrials |
| NCT00243061 | AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma | completed | Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | Aug 27, 2018 | clinicaltrials |
| NCT02155322 | A Phase II Study of Pegylated Interferon Alfa-2b for the Adjuvant Treatment of Melanoma Subjects in Russia (MK-4031-400) | completed | Phase 2 | 33 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 23, 2018 | clinicaltrials |
| NCT01673854 | Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma | completed | Phase 2 | 70 | Bristol-Myers SquibbINDUSTRY | 1 | Jul 24, 2018 | clinicaltrials |
| NCT01064713 | Phase II Study of Tesetaxel in Metastatic Melanoma | completed | Phase 2 | 17 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 17, 2018 | clinicaltrials |
| NCT00074308 | Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers | completed | Phase 1 / Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Jun 20, 2018 | clinicaltrials |
| NCT01174238 | A Two Arm Trial of Axitinib and Carboplatin/Paclitaxel in Melanoma | completed | Phase 2 | 40 | Adil DaudOTHER | 1 | Jun 8, 2018 | clinicaltrials |
| NCT01961115 | Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma | completed | Phase 2 | 11 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 8, 2018 | clinicaltrials |
| NCT00383292 | A Study of Tasisulam in Treating Participants With Malignant Melanoma | completed | Phase 2 | 130 | Eli Lilly and CompanyINDUSTRY | 2 | Jun 6, 2018 | clinicaltrials |
| NCT00804908 | A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma | completed | Phase 2 | 346 | AbbVie (prior sponsor, Abbott)INDUSTRY | 0 | Jun 6, 2018 | clinicaltrials |
| NCT03541148 | Evaluation of Oncoxin-Viusid® in Cutaneous Melanoma | completed | Phase 2 | 20 | Catalysis SLINDUSTRY | 1 | May 30, 2018 | clinicaltrials |
| NCT00450255 | VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery | completed | Phase 2 | 41 | National Cancer Institute (NCI)NIH | 1 | May 24, 2018 | clinicaltrials |
| NCT01323517 | Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity | completed | Phase 2 | 26 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 15, 2018 | clinicaltrials |
| NCT00256282 | Docetaxel and Vinorelbine Plus Sargramostim in Metastatic Malignant Melanoma | completed | Phase 2 | 52 | John P. FruehaufOTHER | 1 | May 3, 2018 | clinicaltrials |
| NCT00938223 | Evaluation of the Immunogenicity of Vaccination With Multiple Synthetic Melanoma Peptides With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With Advanced Melanoma(MEL39) | completed | Phase 2 | 51 | Craig L Slingluff, JrOTHER | 1 | May 2, 2018 | clinicaltrials |
| NCT00626405 | Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by Surgery | completed | Phase 2 | 95 | Alliance for Clinical Trials in OncologyOTHER | 1 | May 1, 2018 | clinicaltrials |
| NCT00101166 | Universal Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)-Producing and CD40L Expressing Bystander Cell Line for Tumor Vaccine in Melanoma | completed | Phase 2 | 43 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Feb 28, 2018 | clinicaltrials |
| NCT00056134 | Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma | completed | Phase 1 / Phase 2 | 23 | University Hospital ErlangenOTHER | 1 | Feb 19, 2018 | clinicaltrials |
| NCT01079741 | Safety Study of Adjuvant Vaccine to Treat Melanoma Patients | completed | Phase 1 / Phase 2 | 34 | Nina BhardwajOTHER | 1 | Feb 13, 2018 | clinicaltrials |
| NCT01693068 | Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma | completed | Phase 2 | 194 | EMD SeronoINDUSTRY | 14 | Jan 5, 2018 | clinicaltrials |
| NCT00726739 | Aldesleukin With or Without Vaccine Therapy in Treating Patients With Stage IV Melanoma | completed | Phase 2 | 21 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT00387751 | Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma | completed | Phase 2 | 14 | National Cancer Institute (NCI)NIH | 1 | Nov 22, 2017 | clinicaltrials |
| NCT01034787 | Study of AntiCTLA4 in Patients With Unresectable or Metastatic Uveal Melanoma | completed | Phase 2 | 11 | AHS Cancer Control AlbertaOTHER | 1 | Oct 27, 2017 | clinicaltrials |
| NCT00715793 | Combination of Decitabine and Temozolomide in the Treatment of Patients With Metastatic Melanoma(UPCI-07-008) | completed | Phase 1 / Phase 2 | 39 | Hussein TawbiOTHER | 1 | Oct 3, 2017 | clinicaltrials |
| NCT01153763 | A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma | completed | Phase 2 | 92 | GlaxoSmithKlineINDUSTRY | 5 | Sep 27, 2017 | clinicaltrials |
| NCT00521001 | Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery | completed | Phase 2 | 49 | Alliance for Clinical Trials in OncologyOTHER | 1 | Aug 14, 2017 | clinicaltrials |
| NCT01252251 | RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma | completed | Phase 2 | 14 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 1, 2017 | clinicaltrials |
| NCT01253564 | A Study of RO5185426 in Previously Treated Melanoma Patients With Brain Metastases | completed | Phase 2 | 24 | Hoffmann-La RocheINDUSTRY | 1 | Jul 31, 2017 | clinicaltrials |
| NCT00107718 | Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma | completed | Phase 2 | 64 | GlaxoSmithKlineINDUSTRY | 2 | Jul 27, 2017 | clinicaltrials |
| NCT01143402 | Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye | completed | Phase 2 | 120 | National Cancer Institute (NCI)NIH | 2 | Jul 26, 2017 | clinicaltrials |
| NCT00949702 | A Study of Vemurafenib in Previously Treated Patients With Metastatic Melanoma | completed | Phase 2 | 132 | Hoffmann-La RocheINDUSTRY | 2 | Jul 25, 2017 | clinicaltrials |
| NCT00434252 | A Study of Bevacizumab With Carboplatin and Paclitaxel Chemotherapy for the First-Line Treatment of Patients With Metastatic Melanoma(BEAM) | completed | Phase 2 | 214 | Genentech, Inc.INDUSTRY | 0 | Jul 18, 2017 | clinicaltrials |
| NCT00062036 | Cyclophosphamide and Fludarabine Followed By Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes in Treating Patients With Metastatic Melanoma | completed | Phase 1 / Phase 2 | 33 | National Institutes of Health Clinical Center (CC)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT00610857 | Safety and Efficacy of Combination HDI and Anti-CTLA4 for Recurrent Inoperable Stage III or Stage IV Melanoma | completed | Phase 2 | 37 | Ahmad TarhiniOTHER | 1 | Jun 22, 2017 | clinicaltrials |
| NCT00125749 | Vaccination of Patients With Stage IV Melanoma With Dendritic Cells | completed | Phase 1 / Phase 2 | 30 | Baylor Research InstituteOTHER | 1 | Jun 12, 2017 | clinicaltrials |
| NCT00397982 | Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant Melanoma(Mel47) | completed | Phase 2 | 17 | National Cancer Institute (NCI)NIH | 1 | Jun 9, 2017 | clinicaltrials |
| NCT01395121 | A Trial Looking at Nilotinib to Treat Acral and Mucosal Melanoma Skin Cancer That Has Spread(NICAM) | completed | Phase 2 | 29 | Institute of Cancer Research, United KingdomOTHER | 1 | Jun 8, 2017 | clinicaltrials |
| NCT01676779 | mRNA Electroporated Autologous Dendritic Cells for Stage III/IV Melanoma(DC-MEL) | completed | Phase 2 | 88 | Universitair Ziekenhuis BrusselOTHER | 1 | May 24, 2017 | clinicaltrials |
| NCT00831545 | Study to Evaluate the Efficacy and Safety of Temozolomide in Subjects With Brain Metastases of Either Malignant Melanoma, Breast, or Non-small Cell Lung Cancer (P02064) | completed | Phase 2 | 162 | Merck Sharp & Dohme LLCINDUSTRY | 0 | May 9, 2017 | clinicaltrials |
| NCT00093119 | Trial of ABI-007 in Previously Treated Patients With Metastatic Melanoma | completed | Phase 2 | 75 | CelgeneINDUSTRY | 1 | Apr 26, 2017 | clinicaltrials |
| NCT01164007 | A Study of Bevacizumab (Avastin) in Combination With Dacarbazine in Participants With Unresectable/Metastatic Melanoma | completed | Phase 2 | 40 | Hoffmann-La RocheINDUSTRY | 1 | Apr 21, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Jan 24, 2019source: clinicaltrials